Get Support

Learn Mode

ZBH - Zimmer Biomet Holdings, Inc

37

$82.80

-$9.79 (-10.573%)

At market close

$83.46

$0.66 (0.791%)

After Hours 4/28/26, 11:36 PM

3.57/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

ZBH

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$15.80B

Industry

Health Care

EPS (TTM)

$3.55

P/E (TTM)

22.42

Div & Yield

$0.96 (1.16%)

FCF Payout Ratio

16.36%

P/S (TTM)

1.92

P/B

1.24

Diluted Shares

197.80M

Ex-Dividend

2026-03-31

Next Earnings

04-28

Forward P/E

9.49

Payout Ratio

25.99%

P/FCF (TTM)

14.11

FCF Yield

7.09%

Earnings Yield

4.46%

52 Week Range

Score Card

Explore Scores Tab

3.57

Good

Zimmer Biomet Holdings, Inc has grown revenue at 7.2% over the past year, which suggests sales are increasing. Also, it has seen its diluted average shares outstanding decrease by -1.1% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

2.00

Bad

Management

1.00

Very Bad

Growth

2.00

Bad

Profitability

3.00

Average

Fin. Health

3.00

Average

Dividends

1.00

Very Bad

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-03 16:03:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:20:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:19:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:18:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:17:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:17:10

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:16:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:15:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:13:58

Form ARS

Unknown Form Type

Filed on 2026-04-01 07:07:06

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-01 07:03:16

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-01 07:00:44

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-12

High:

$134.74

62.7%

Avg:

$105.44

27.3%

Low:

$88.88

7.3%

(% change is relative to the current stock price: $82.80)

Analyst Recommendations

Go to Analyst Tab

3.32

Average

9%

Strong Buy (3)

24%

Buy (8)

59%

Hold (20)

9%

Sell (3)

0%

Strong Sell (0)

About

Website
https://www.zimmerbiomet.com/en
Address
345 E Main St, Warsaw Indiana INDIANA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1136869

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

IPO Date

2001-07-25

Industry

Health Care

Total Employees

17,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services